Contribute Try STAT+ Today

ASCO

Most Read

Cancer Chemotherapy

Health By Sharon Begley

Cancer patients keep getting aggressive end-of-life treatment, despite lack of benefit

Pancreatic Cancer Cells

Biotech By Adam Feuerstein

Merus drug shows potential as treatment for rare type of pancreatic cancer

3D structure of melanoma cell

Biotech By Matthew Herper

In a step forward for immunotherapy, new Bristol Myers drug slows melanoma in study

ASCO for one

Adam's Take By Adam Feuerstein

ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress

Vacutainers

Biotech By Matthew Herper

Grail, a deep-pocketed startup, shows ‘impressive,’ if early, results for cancer blood test

purple lungs ct

Biotech By Adam Feuerstein

AstraZeneca study results could change treatment for certain early-stage lung cancer patients

breast cancer India

First Opinion By Maura McCarthy

Early diagnosis, not cancer drug breakthroughs, is the best way to fix the global scourge of breast cancer

Cervical cancer cells

Biotech By Adam Feuerstein

Iovance reports progress with its custom cell therapies for solid tumors

All Coverage

AstraZeneca building

Health By Matthew Herper

AstraZeneca drug prevents breast cancer caused by BRCA mutations from returning

Biotech By Matthew Herper

STAT+ Conversations: A look ahead to ASCO 2021

advertisement

Biotech By Adam Feuerstein

Allogene’s blood cancer data show durability of off-the-shelf CAR-T cells

Pharma By Adam Feuerstein

With new data, J&J’s CAR-T drug benefits myeloma patients with less advanced disease

ASH19 Lymphoma

Biotech By Adam Feuerstein

Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows

red/orange lung cancer

Biotech By Adam Feuerstein

Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study

ASH19 Lymphoma

Biotech By Adam Feuerstein

Some blood cancer patients see remission with Allogene’s off-the-shelf CAR-T cells, early data show

The Readout LOUD By Adam Feuerstein and Matthew Herper

Listen: A special episode from the halls of the ASCO meeting

ASCO 2019 signage

Biotech By Adam Feuerstein and Matthew Herper

What you missed at ASCO? A lot, as cancer research hastens on

Lung Cancer Cells - for ASCO

Biotech By Adam Feuerstein

At ASCO, targeted lung cancer drugs shrink tumors caused by rare genetic mutations

DNA tech connection

Biotech By Matthew Herper

Tempus, a well-funded company run by a Groupon billionaire, wants to get patients into clinical trials

tennis balls on a blue background

Biotech By Adam Feuerstein

Amgen’s drug — targeting an ‘undruggable’ cancer protein — shrank tumors in half of patients

Affordable Care Act - insurance sign up

Health By Matthew Herper

The Affordable Care Act erased a racial disparity in cancer care, a new study says

Pharma By Matthew Herper

Forget controversy. AstraZeneca’s dynamic duo wants to dominate the market for cancer drugs

Breast Cancer cells

Biotech By Matthew Herper

Novartis hopes new survival data will help its Kisqali take on Pfizer’s Ibrance. It probably won’t

blue sky moderna

Biotech By Adam Feuerstein

Moderna makes ASCO debut with an early look at a personalized cancer vaccine

Lung cancer cell dividing

Biotech By Matthew Herper

Turning Point Therapeutics drug shows benefits for patients with rare lung cancer gene

Biotech By Jonathan Saltzman — Boston Globe

Epizyme seeks early approval for drug to treat ultra-rare tumors

Cancer Financial Toxicity

Pharmalot By Ed Silverman

More new cancer therapies are being launched than ever before, but spending is skyrocketing

Biotech By Matthew Herper

Merck’s R&D boss sees more promise in his big drug and a $1 billion deal

Cash back

Pharmalot By Ed Silverman

New tools for assessing drug value haven’t caught on with payers — yet

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Immunomedics abstract booted from cancer conference